𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases

✍ Scribed by Maisie Lo; Yu-Zhuo Wang; Peter W. Gout


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
163 KB
Volume
215
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The x cystine/glutamate antiporter is a major plasma membrane transporter for the cellular uptake of cystine in exchange for intracellular glutamate. Its main functions in the body are mediation of cellular cystine uptake for synthesis of glutathione essential for cellular protection from oxidative stress and maintenance of a cystine:cysteine redox balance in the extracellular compartment. In the past decade it has become evident that the x transporter plays an important role in various aspects of cancer, including: (i) growth and progression of cancers that have a critical growth requirement for extracellular cystine/cysteine, (ii) glutathione‐based drug resistance, (iii) excitotoxicity due to excessive release of glutamate, and (iv) uptake of herpesvirus 8, a causative agent of Kaposi's sarcoma. The x transporter also plays a role in certain CNS and eye diseases. This review focuses on the expression and function of the x transporter in cells and tissues with particular emphasis on its role in disease pathogenesis. The potential use of x inhibitors (e.g., sulfasalazine) for arresting tumor growth and/or sensitizing cancers is discussed. J. Cell. Physiol. 215: 593–602, 2008. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


The x cystine/glutamate antiporter (xCT)
✍ Nic E. Savaskan; Eric Hahnen; Ilker Y. Eyüpoglu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

## Abstract This article was published online on 4 May 2009. An error was subsequently identified. This notice is included in the online and print versions to indicate that both have been corrected 8 June 2009.

ErbB4 increases the proliferation potent
✍ Alex Starr; Joel Greif; Akiva Vexler; Maia Ashkenazy-Voghera; Valery Gladesh; Ch 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 218 KB 👁 1 views

## Abstract Clinical and experimental data suggest that ErbB‐4, a member of the epidermal growth factor receptor family, may have a role in cancer progression and response to treatment. We found recently, using a retrospective clinical analysis, that expression of ErbB‐4 receptor is correlated with